These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20080378)

  • 1. [Successful use of recombinant factor VIIa in the control of a massive bleeding in two patients with biventricular assist device (Thoratec)].
    Fritsch N; Pouquet O; Roux B; Abdelmoumen Y; Janvier G
    Ann Fr Anesth Reanim; 2010 Jan; 29(1):45-7. PubMed ID: 20080378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.
    Tarzia V; Buratto E; Bortolussi G; Paolini C; Bejko J; Bottio T; Gerosa G
    Artif Organs; 2015 Mar; 39(3):248-53. PubMed ID: 25065398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five days of no anticoagulation or antiplatelet therapy and NovoSeven administration in a HeartWare HVAD patient.
    Saeed D; Albert A; Kamiya H; Maxhera B; Westenfeld R; Lichtenberg A
    Artif Organs; 2012 Aug; 36(8):751-3. PubMed ID: 22607278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
    Yadav SP; Sachdeva A; Bhat S; Katewa S
    Pediatr Hematol Oncol; 2010 Feb; 27(1):24-30. PubMed ID: 20121552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
    Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
    Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drugs to reduce transfusion needs during surgery].
    Pleym H
    Tidsskr Nor Laegeforen; 2008 Apr; 128(7):829-30. PubMed ID: 18389031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic agents: which is better?
    Daban JL; de Saint Maurice G; Blot RM; Ausset S
    J Trauma; 2010 Dec; 69(6):1636. PubMed ID: 21150543
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid.
    Huvers F; Slappendel R; Benraad B; van Hellemondt G; van Kraaij M
    Neth J Med; 2005 May; 63(5):184-6. PubMed ID: 15952489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
    Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
    Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
    Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
    Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device.
    Potapov EV; Pasic M; Bauer M; Hetzer R
    Ann Thorac Surg; 2002 Dec; 74(6):2182-3. PubMed ID: 12643420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report.
    Matei A; Dolan S; Andrews J; Rivard GÉ
    J Obstet Gynaecol Can; 2016 Feb; 38(2):160-3. PubMed ID: 27032741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
    Alberca I; Asuero MS; Bóveda JL; Carpio N; Contreras E; Fernández-Mondéjar E; Forteza A; García-Erce JA; García de Lorenzo A; Gomar C; Gómez A; Llau JV; López-Fernández MF; Moral V; Muñoz M; Páramo JA; Torrabadella P; Quintana M; Sánchez C
    Med Clin (Barc); 2006 Jul; 127 Suppl 1():3-20. PubMed ID: 17020674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period.
    Tanchev S; Platikanov V; Karadimov D
    Acta Obstet Gynecol Scand; 2005 Apr; 84(4):402-3. PubMed ID: 15762974
    [No Abstract]   [Full Text] [Related]  

  • 16. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recombinant activated factor VII for perioperative bleeding].
    López R; Aeschlimann N; Carvajal C; Lema G
    Rev Med Chil; 2009 Jun; 137(6):837-43. PubMed ID: 19746288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
    Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
    Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
    Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of recombinant activated factor VII to control haemorrhage following exenteration and massive transfusion in coagulopathic patients].
    Vucelić D; Kecmanović D; Pavlov M; Ranković V; Masirević V; Djukić A; Palibrk I; Tomasević L; Velicković J; Milovanović A
    Srp Arh Celok Lek; 2008 Sep; 136 Suppl 3():231-9. PubMed ID: 19562875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.